___

• Levine AJ. p53, the cellular gatekeeper for growth and division. Cell, 1997; 88(3): 323-331.
• Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res, 1994; 22(17): 3551- 3555.
• DeWolf WC. p53: an important key to understanding urologic cancer. AUA Update Series, 1995; 15: 258.
• Smith ND, Rubenstein JN, Eggener SE, et al. The p53 Tumor Suppressor Gene and Nuclear Protein: Basic Science Review and Relevance in the Management of Bladder Cancer (Clinical Urology: Review Article). J Urol, 2003; 169(4): 1219-1228.
• Vet JA, Witjes JA, Marras SA, et al. Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer. Clin Cancer Res, 1996; 2(6): 1055-1061.
• Zlotta AR, Noel J-C, Fayt I, et al. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol, 1999; 161(3): 792-798.
• Fleshner N, Kapusta L, Ezer D, Herschorn S, Klotz L. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol, 2000; 164(4): 1177-1182.
• Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD. p53 alteration in gastric precancerous lesions. Am J Pathol, 1994; 144(3): 511-517.
• Moore LE, Smith AH, Eng C, et al. p53 alterations in bladder tumors from arsenic and tobacco exposed patients. Carcinogenesis, 2003; 24(11); 1785-1791.
• McCredie M, Stewart JH, Ford JM, et al. Phenacetin- containing analgesics and cancer of the bladder or renal pelvis in women. Br J Urol, 1983; 55(2): 220-224.
• Piper JM, Tonocia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med, 1985; 313(5): 292-295.
• LaRue H, Allard P, Simoneau M, et al. p53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis, 2000; 21(1): 101-106.
• Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis (Review). Cancer Res,1994; 54(18): 4855-4878.
• Sidransky D, von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science, 1991; 252(5006): 706-709.
• Yoshimura I, Kudoh J, Saito S, Tazaki H, Shimizu N. p53 gene mutation in recurrent superficial bladder cancer. J Urol, 1995; 153(5): 1711-1715.
• Taylor JA, Li Y, He M, et al. p53 mutations in bladder tumors from arylamine-exposed workers. Cancer Res, 1996; 56(2): 294-298.
• Xu X, Stower MJ, Reid IN, Garner RC, Burns PA. Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers. Clin Cancer Res, 1996; (10): 1795-1800.
• Lin HY, Huang CH, Wu WJ, Chou YH, Fan PL, Lung FW. Mutation of the p53 tumor suppressor gene in transitional cell carcinoma of the urinary tract in Taiwan. Kaohsiung J Med Sci, 2005; 21(2): 57-64.
• http://www.akdeniz.edu.tr/tip/web/ders_form/ UROLOJI/baykara_mesane.htm Erişim 20.06.2005
• Lorenzo Romero JG, Salinas Sanchez AS, Gimenez Bachs JM. p53 Gene mutations in superficial bladder cancer. Urol Int, 2004; 73(3): 212-218.
• Oyasu R, Nan L, Szumel RC, Kawamata H, Hirohashi S. p53 gene mutations in human urothelial carcinomas: analysis by immunohistochemistry and single-strand conformation polymorphism. Mod Pathol, 1995; 8(2): 170-176.
• Phillips H.A., Howard G.C., Miller W.R. p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer. Br J Cancer, 2000; 82(1): 136-41.
• Lorenzo Romero JG, Salinas-Sanchez AS, Gimenez- Bachs JM, et al. Prognostic implications of p53 gene mutations in bladder tumors. J Urol, 2003; 169(2): 492-499.